Alpha 2.0
Login Register
» Articles » PMID: 37808972

Statistical Explanation of the Protective Effect of Four COVID-19 Vaccine Doses in the General Population

Overview
Journal Front Public Health
Specialty Public Health
Date 2023 Oct 9
PMID 37808972
Authors
Humberto Reyes
Constanza Mendez
Alexis M Kalergis
Affiliations
Soon will be listed here.
Abstract

Objectives: To assess the effectiveness of four doses of the vaccine against SARS-CoV-2 in the general population and the impact of this on the severity of the disease by age group.

Methods: By using data from the health authority public data base, we build statistical models using R and the GAMLSS library to explain the behavior of new SARS-CoV-2 infections, active COVID-19 cases, ICU bed requirement total and by age group, and deaths at the national level.

Results: The four doses of vaccine and at least the interaction between the first and second doses were important explanatory factors for the protective effect against COVID-19. The for new cases per day was 0.5644 and for occupied ICU beds the is 0.9487. For occupied ICU beds for >70 years is 0.9195 and with the interaction between 4 doses as the main factor.

Conclusions: Although the increase in the number of vaccine doses did not adequately explain the decrease in the number of COVID-19 cases, it explained the decrease in ICU admissions and deaths nationwide and by age group.

References
1.
He Q, Mao Q, An C, Zhang J, Gao F, Bian L . Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021; 10(1):629-637. PMC: 8009122. DOI: 10.1080/22221751.2021.1902245. View
2.
Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View
3.
Reyes H, Diethelm-Varela B, Mendez C, Rebolledo-Zelada D, Lillo-Dapremont B, Munoz S . Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape. Front Public Health. 2022; 10:815036. PMC: 9364872. DOI: 10.3389/fpubh.2022.815036. View
4.
Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M . Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021; 600(7890):701-706. DOI: 10.1038/s41586-021-04120-y. View
5.
Jara A, Undurraga E, Zubizarreta J, Gonzalez C, Pizarro A, Acevedo J . Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022; 10(6):e798-e806. PMC: 9034854. DOI: 10.1016/S2214-109X(22)00112-7. View